Immuneering doses first patient in Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer

Immuneering

Immuneering

IMRX

0.00
  • Immuneering dosed the first patient in MAPKeeper 301, a global pivotal Phase 3 trial in first-line metastatic pancreatic cancer.
  • The study tests atebimetinib with modified gemcitabine and nab-paclitaxel versus standard gemcitabine and nab-paclitaxel alone.
  • Earlier survival and tolerability results were presented this year, supporting the move into a registrational trial.
  • Topline Phase 3 results, including overall survival, are expected in mid-2028.
  • The readout will guide whether atebimetinib can support a new first-line option in a high-need market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.